Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH).

Trial Profile

Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2015

At a glance

  • Drugs CER 001 (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Pharmacodynamics
  • Acronyms MODE
  • Sponsors Cerenis Therapeutics
  • Most Recent Events

    • 01 May 2015 Results published in the American Heart Journal.
    • 04 Feb 2015 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.
    • 02 Jun 2014 According to a Cerenis media release, results were presented at the 82nd Congress of the European Atherosclerosis Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top